Companies › LG Chem
4 active drug programs in 16 registered trials: 8 Phase 2, 4 Phase 4, 3 Phase 3, 1 Phase 1; Genitourinary, Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 4 | Central Precocious Puberty; Prostate Cancer; Androgen Deprivation Therapy; Advanced Salivary Gland Carcinoma … | Aug 2029 |
| Fang Le Shu (Follitrope) Recombinant follicle-stimulating hormone (rFSH) | FSHR | Phase 4 | Female Infertility | – |
| LBVD Fully liquid hexavalent vaccine containing diphtheria toxoid, tetanus toxoid, whole cell p | – | Phase 2 | Diphtheria | Feb 2028 |
| LB-LR1109 | – | Phase 1 | Non-small Cell Lung Cancer(NSCLC) | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06921395 | Fang Le Shu (Follitrope) | Phase 4 | Female Infertility | Genitourinary | Dec 2025 |
| NCT06627530 | Leuprolide | Phase 4 | Prostate Cancer | Oncology | Dec 2026 |
| NCT05924256 | Leuprolide | Phase 2 | Advanced Salivary Gland Carcinoma | Oncology | Dec 2026 |
| NCT05478083 | Leuprolide | Phase 2 | Polycystic Liver Disease | Gastroenterology | Jun 2027 |
| NCT04302454 | Leuprolide | Phase 3 | Prostate Cancer | Oncology | Oct 2027 |
| NCT06332755 | LB-LR1109 | Phase 1 | Non-small Cell Lung Cancer(NSCLC) | Oncology | Nov 2027 |
| NCT01492972 | Leuprolide | Phase 3 | Prostate Cancer | Oncology | Dec 2027 |
| NCT07158021 | Leuprolide | Phase 2 | Anatomic Stage I Breast Cancer AJCC v8 | Oncology | Jan 2028 |
| NCT06947499 | LBVD | Phase 2 | Diphtheria | Infectious disease | Feb 2028 |
| NCT06145308 | Leuprolide | Phase 2 | Salivary Gland Carcinoma | Oncology | Jul 2028 |
| NCT07848828 | Leuprolide | Phase 4 | Androgen Deprivation Therapy | Genitourinary | Jul 2028 |
| NCT02221999 | Leuprolide | Phase 2 | Tubular Breast Cancer | Oncology | Jan 2029 |
| NCT07710430 | Leuprolide | Phase 4 | Central Precocious Puberty | Metabolic and endocrine | Aug 2029 |
| NCT07455903 | Leuprolide | Phase 2 | Prostate Cancer | Oncology | Feb 2030 |
| NCT06397703 | Leuprolide | Phase 2 | Prostate Cancer | Oncology | Apr 2030 |
| NCT05781217 | Leuprolide | Phase 3 | Prostate Cancer | Oncology | Dec 2032 |
Calico Life Sciences Everest Medicines (China) Sumitomo Pharma Switzerland Dong-A ST Kissei Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.